APTO
Aptose Biosciences Inc

7,091
Loading...
Loading...
News
all
press releases
Aptose Biosciences Faces Nasdaq Delisting Challenge
Aptose Biosciences (APS) has provided an announcement. Aptose Biosciences Inc. has been notified by Nasdaq that their stock has not met the minimum...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Aptose Biosciences (NASDAQ:APTO) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO - Free Report) (TSE:APS) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright...
Ticker Report·1y ago
News Placeholder
Aptose Biosciences (NASDAQ:APTO) Rating Increased to Hold at StockNews.com
Aptose Biosciences (NASDAQ:APTO - Get Free Report) (TSE:APS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on...
Zolmax·1y ago
News Placeholder
Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Decreases By 28.7%
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 50,200...
Ticker Report·1y ago
News Placeholder
Aptose Biosciences Inc. (NASDAQ:APTO) Receives $36.50 Consensus Price Target from Brokerages
Shares of Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) have earned an average rating of Buy from the five research firms that are currently covering the...
Ticker Report·1y ago
News Placeholder
Q4 2023 Aptose Biosciences Inc Earnings Call Transcript
Related Stocks: NAS:APTO...
GuruFocus·1y ago
News Placeholder
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired...
Globe Newswire·1y ago
News Placeholder
Aptose Biosciences Q4 2023 Earnings Preview
Aptose Biosciences Q4 2023 Earnings Preview...
SeekingAlpha.com: All News·1y ago
News Placeholder
Aptose Biosciences's Earnings: A Preview
read more...
Benzinga·1y ago
News Placeholder
Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from Brokerages
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) has earned a consensus rating of Buy from the six brokerages that are presently covering the stock, MarketBeat...
Zolmax·1y ago

Latest APTO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.